Literature DB >> 33942148

Evolution of psychosocial burden and psychiatric symptoms in patients with psychiatric disorders during the Covid-19 pandemic.

Michael Belz1, Philipp Hessmann1, Jonathan Vogelgsang1,2, Ulrike Schmidt1,3,4, Mirjana Ruhleder1, Jörg Signerski-Krieger1, Katrin Radenbach1, Sarah Trost1,5, Björn H Schott1,6,7, Jens Wiltfang1,6,8, Claus Wolff-Menzler1, Claudia Bartels9.   

Abstract

The Covid-19 pandemic highly impacts mental health worldwide. Patients with psychiatric disorders are a vulnerable risk population for worsening of their condition and relapse of symptoms. This study investigates the pandemic-related course of psychosocial burden in patients with pre-existing mental disorders. With the newly developed Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) psychosocial burden has been traced retrospectively (1) before the pandemic (beginning of 2020), (2) at its beginning under maximum lockdown conditions (March 2020), and (3) for the current state after maximum lockdown conditions (April/May 2020). The Goe-BSI also integrates the Adjustment Disorder New Module (ADNM-20), assesses general psychiatric symptoms, and resilience. A total of 213 patients covering all major psychiatric disorders (ICD-10 F0-F9) were interviewed once in the time range from April, 24th until May 11th, 2020. Across all diagnoses patients exhibited a distinct pattern with an initial rise followed by a decline of psychosocial burden (p < 0.001, partial η2 = 0.09; Bonferroni-corrected pairwise comparisons between all three time-points: p < 0.05 to 0.001). Female gender and high ADNM-20 scores were identified as risk factors for higher levels and an unfavorable course of psychosocial burden over time. Most psychiatric symptoms remained unchanged. Trajectories of psychosocial burden vary in parallel to local lockdown restrictions and seem to reflect an adaptive stress response. For female patients with pre-existing mental disorders and patients with high-stress responses, timely and specific treatment should be scheduled. With the continuation of the pandemic, monitoring of long-term effects is of major importance, especially when long incubation times for the development of mental health issues are considered.
© 2021. The Author(s).

Entities:  

Keywords:  Adjustment disorder; Coronavirus; Mental health; Psychosocial stress; SARS-CoV-2

Mesh:

Year:  2021        PMID: 33942148      PMCID: PMC8092366          DOI: 10.1007/s00406-021-01268-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


Introduction

Starting in late 2019, the Covid-19 pandemic spread worldwide causing a steep increase in mortality and severe somatic complications in millions. As a secondary consequence, the pandemic’s dynamics together with social restrictions constitute a mental health threat of considerable magnitude, most likely resulting in psychological sequelae of hitherto unknown extent. Thus, an increased incidence of psychiatric disorders is expected that may peak later than somatic cases and bear the risk of longer disease duration requiring specific treatment [1]. An emerging body of evidence already demonstrates increased rates of first-onset mental health disorders in healthcare professionals [2-8], SARS-CoV-2 infected patients [9-11], and in the general population [4, 7, 12–16]. Patients with pre-existing psychiatric conditions might be particularly vulnerable [17] and thus react with worsening, or relapse of symptoms potentially due to a reduced level of functioning and poorer availability of coping strategies [1]. A reduced access to psychiatric/psychotherapeutic services following the pandemic and treatment-challenging mental health conditions [17] may also contribute to a poor outcome. Accordingly, patients with psychiatric disorders have been found to be more susceptible to contracting Covid-19 [17, 18], to have lower life expectancies, and poorer physical health outcomes in general [19]. Despite this, only a few studies have addressed patients with pre-existing mental health disorders so far. In a systematic review [20], only two of 43 included studies addressed patients with mental health issues and concluded a worsening of their condition related to the pandemic: first, a questionnaire survey revealed a general deterioration of mental health in 20.9% of assessed patients with psychiatric disorders in China, but psychiatric diagnoses were not reported [21]. Second, the other study specifically devoted to patients with eating disorders in Spain found an increase in symptomatology and additional anxiety symptoms [22]. A recent study targeting the general population in Italy suggested a higher risk for developing severe depression and anxiety symptoms in respondents of an online survey with a self-reported history of mental health problems [23]. Similarly, higher levels of anxiety, depression, stress and insomnia were found in 76 patients compared to healthy controls during strict lockdown measures in China, and high rates of Post-traumatic Stress Disorder (PTSD) symptoms [24]. Yet, this patient sample was restricted to unipolar depression (F32, F33) and a small range of anxiety disorders (F41, F41.8). Few studies have also investigated specific psychiatric subgroups. A higher risk for developing symptoms of anxiety and PTSD was found in pregnant women with a self-reported history of anxiety or depression [25]. Evidence regarding the influence on addictive behavior is yet inconclusive [26, 27]. Clinical deterioration seems to be pronounced in Obsessive-Compulsive Disorder, including an increased prevalence of suicidal ideations [28]. For adult Attention Deficit Hyperactivity Disorder, high levels of emotional distress were reported, but with an unclear association to pandemic-related changes [29]. Irrespective of the population investigated, most studies focused on symptoms of anxiety, depression, PTSD, stress, insomnia, and self-harm/suicidality related to the pandemic [2–6, 8, 12–16, 23–25, 28–32]. We suppose that only a minority has been confronted with traumatic events as defined in DSM 5 or ICD-10, but rather experienced a critical and enduring stressful life period resulting in symptoms of adjustment disorder (rather than in PTSD). However, adjustment disorder as mental health outcome of the Covid-19 pandemic has only received little attention [29, 31, 33]. In sum, pandemic-related data for psychosocial burden of psychiatric patient populations is very limited, and most importantly, information on its evolution in pre-existing mental health conditions during the pandemic is scarce. The aim of this study was to trace back the stress response of patients with current psychiatric disorders, starting from their current state in April/May 2020 back to time-points before and at the beginning of the pandemic. We thereby aimed (1) to investigate how the continuing pandemic and different lockdown regulations impact the course of psychosocial burden in (2) a patient sample with a broad spectrum of major psychiatric disorders, and (3) additionally focused on the assessment of adjustment disorder symptoms, general psychiatric symptoms and resilience.

Material and methods

Study sample

To cover a preferably wide spectrum of psychiatric diseases in this study, participants were eligible if they were (1) ≥ 18 years old, (2) treated in the Department of Psychiatry and Psychotherapy at the University Medical Center Goettingen, Germany between 10/2019 and 03/2020, (3) not currently hospitalized, and if (4) they had a current diagnosis within the spectrum of “mental and behavioral disorders” (ICD-10: F00-F99). All diagnoses, primary and secondary, as well as comorbid somatic diagnoses, were determined by their treating clinicians (psychiatric residents, board-certified psychiatrists, psychologists, or licensed psychotherapists). Primary diagnosis was defined as treatment diagnosis, i.e. the primary cause of psychiatric/psychotherapeutic consultation and treatment. Exclusion criteria comprised the inability to give informed consent. From a total of 5223 patients with psychiatric disorders consulting our clinic at least once during 10/2019 and 03/2020, 1003 patients with dementia were excluded a priori due to their inability to give informed consent. Of the remaining 4220 patients, a convenience sample of 316 eligible patients was approached, finally resulting in N = 213 study participants providing informed consent and study data (participation rate: 67.4%). Due to contact restrictions during the pandemic, oral/verbal informed consent was obtained from all patients prior to the study, was witnessed and formally recorded. Written informed consent was obtained later. Consent was both obtained for participation in the study, and publication of individual anonymized data in a journal.

Study design

Participants were interviewed via telephone at one time-point in the acute phase of maximum social restrictions (“lockdown”) during the Covid-19 pandemic in Lower Saxony, Germany, from April, 24th until May, 11th, 2020 (please see Supplementary Table S2). All interviews were performed by highly qualified and specialized clinicians, and—in 80.3% of cases—interviews were conducted by the patients’ clinician/therapist. All interviewers underwent a rater training prior to data collection. In sum, 28 therapists participated in data collection.

Study measures: the Goettingen psychosocial burden and symptom inventory (Goe-BSI)

For the present study, we developed the Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) to be applied as a standardized and structured telephone interview. In total, the interview contains 77 items covering the following sections: (1) clinical and demographic data, and Covid-19 related information (e.g., being tested for Covid-19 virus, being sent to quarantine, allocation to a Covid-19 risk group, current symptoms suspicious of a SARS-CoV-2 infection), (2) course of psychosocial burden during the pandemic, (3) symptoms of an adjustment disorder due to the pandemic (assessed by the Adjustment Disorder New Module – 20 Item version [ADNM-20] [34]), (4) general psychiatric symptoms, and (5) resilience. Patients’ estimations for psychosocial stress, psychiatric symptoms and quality of life on a 10-point Likert scale were combined to measure psychosocial burden. All items were inversely scaled with lower scores indicating higher psychosocial burden (0: It could not be worse; 10: It could not be better). Participants were asked to rate these three items for their current state (April/May 2020), and retrospectively for a time before the pandemic (i.e. January/February 2020) and for the beginning phase of the pandemic when maximum lockdown regulations were active in Germany (mid-March, 2020). These three ratings allowed to generate a retrospective pseudo-course of psychosocial burden during the evolution of the pandemic (primary outcome). Cronbach’s α yielded good to excellent internal consistencies for all three-item groups: (1) before (α = 0.84), (2) at the beginning of the pandemic (α = 0.86), and for the current state (α = 0.90). Please refer to Supplementary Information S1 for additional information on validity for the primary outcome. The ADNM-20 is an established and validated instrument to measure psychological reactions to stressful life events. The pandemic was pre-defined as stressor (chronic life event), and 20 items were to be answered on a frequency scale from 1 (never) to 4 (often) in relation to this stressor (sum score ranges from 20 to 80 points, ≥ 48 points denote high risk for adjustment disorder) [35]. A total of 22 items were included to assess general psychiatric symptoms across all ICD-10 F-axes in relation to the pandemic (e.g., “I have become more vigilant than before the corona-crisis”) with answers ranging from 0 (strongly disagree) to 10 (strongly agree). The same scale was used for two final items focusing on resilience (e.g., “The pandemic also holds opportunities for me.”). In some cases, free-response sections allowed for explaining self-reports in more detail. The interview with a duration of approximately 30 min per patient is available in a paper pencil and an online version (LimeSurvey). Personal data were pseudonymized.

Statistical analyses

IBM SPSS Statistics 26 was used for data analysis. For descriptive representation, we computed means (M), standard deviations (SD) and Pearson correlations (r)1 for metric variables. To analyze the course of psychosocial burden during the pandemic (primary outcome), we used multiple general linear models (GLM) for repeated measures. All models accounted for one level of dependency in our dataset: Three measurements were added as within-subjects factor; psychosocial burden (1) before the pandemic, (2) at the beginning of the pandemic, (3) at the present moment (current state). Additionally, we added multiple between-subjects factors (e.g., ICD-10 F-axes) and gender as covariate (please see results for a detailed description of each GLM). Missing data can be derived from degrees of freedom for each model. For multiple comparisons, p-values were corrected within each model, using the Bonferroni method (initial significance: p < 0.05, two-tailed). Exploratory analyses of the ADNM-20 sum score additionally included UNIANOVA and t-tests (please see results for details).

Results

Basic characteristics of the study sample

A total of N = 213 patients at the Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, were included and underwent telephone interview using the Goe-BSI. The total sample covered an age range from 18 to 95 years (M = 42.24, SD = 16.93). 44.1% of participating patients (n = 94) were male, 42.7% (n = 91) were female. 13.1% (n = 28) were of non-binary gender and/or were diagnosed with a gender identity disorder (ICD-10: F64. *). Among the most frequent of the 56 main/primary ICD-10 diagnoses were the following mental disorders (see Table 1 for details): (1) F64.0 (13.1%, n = 28), (2) F33.2 (8.5%, n = 18), (3) F84.5 (7.0%, n = 15), (4) F20.0 (6.6%, n = 14), and (5) F33.1 (6.6%, n = 14). Categorized by F-axes, the five most frequent were (1) affective disorders (F3, 36.6%, n = 78), (2) neurotic, stress-related and somatoform disorders (F4, 16.4%, n = 35), (3) disorders of adult personality and behavior (F6, 16.4%, n = 35), (4) schizophrenia, schizotypal and delusional disorders (F2, 14.6%, n = 31), and (5) disorders of psychological development” (F8, 9.4%, n = 20). Overall, n = 16 patients (7.5%) had been tested for Covid-19 (n = 1 positive), n = 11 (5.2%) had been quarantined. A total of n = 73 patients (34.3%) belonged to one of the risk groups for a severe course of a SARS-CoV-2 infection. Please also see Table 1 for details of psychotropic medication.
Table 1

Clinical characterization of the study sample

(A) Main F-diagnoses (ICD-10)
F20.0 Paranoid schizophrenia14 (6.6%)
F25.1 Schizoaffective disorder, depressive type8 (3.8%)
F31.3 Bipolar affective disorder, manic episode12 (5.6%)
F32.2 Severe depressive episode10 (4.7%)
F33.1 Recurrent depressive disorder, moderate episode14 (6.6%)
F33.2 Recurrent depressive disorder, severe episode18 (8.5%)
F41.2 Mixed anxiety and depressive disorder7 (3.3%)
F43.1 Post-traumatic stress disorder7 (3.3%)
F64.0 Transsexualism28 (13.1%)
F84.5 Asperger’s syndrome15 (7.0%)
Others66 (31.0%)

Frequency (%). (A) F-diagnoses n ≤ 5 are summarized as “others”; (B) allocation of all F-diagnoses to the corresponding F-axes; (C) frequencies of psychotropic medication adds up to > 100% due to combination therapies. SSRI = selective serotonin reuptake inhibitors; SNRI = serotonin and norepinephrine reuptake inhibitors; SSNRI = selective serotonin and norepinephrine reuptake inhibitors; 1category “other antidepressants” (serotonin modulator, dual serotonergic antidepressants, MAO-inhibitor, atypical); 2combination of two or more antidepressants; N = 213 patients

Clinical characterization of the study sample Frequency (%). (A) F-diagnoses n ≤ 5 are summarized as “others”; (B) allocation of all F-diagnoses to the corresponding F-axes; (C) frequencies of psychotropic medication adds up to > 100% due to combination therapies. SSRI = selective serotonin reuptake inhibitors; SNRI = serotonin and norepinephrine reuptake inhibitors; SSNRI = selective serotonin and norepinephrine reuptake inhibitors; 1category “other antidepressants” (serotonin modulator, dual serotonergic antidepressants, MAO-inhibitor, atypical); 2combination of two or more antidepressants; N = 213 patients

Course of psychosocial burden (primary outcome)

Total sample

Psychosocial burden varied significantly between all time-points (GLM: F(2, 418) = 39.12, p < 0.001, partial η2 = 0.09, all Bonferroni-corrected pairwise comparisons p < 0.05 to 0.001; see Fig. 1a). Thereby, an increase of psychosocial burden from the time-point before the pandemic (M = 6.14, SD = 2.04) to the beginning of the pandemic/lockdown (M = 5.29, SD = 2.04) was followed by a relief of psychosocial burden over time (current state: M = 5.63, SD = 2.26). However, the psychosocial burden at the time of the interview (current state) was still increased compared to the time-point before the pandemic (please note the inverse scaling of psychosocial burden).
Fig. 1

Course of psychosocial burden in patients with psychiatric disorders during different phases of the Covid-19 pandemic. a Course of the total sample (N = 210); differentiated by b gender (binary); c ICD-10 F-axes; d the ADNM-20 cut-off value indicating a high risk for adjustment disorder.* p < 0.05, ** p < 0.01, *** p < 0.001. Mean values with 95%-CIs (a, b, d) and Bonferroni corrected pairwise comparisons (a, b, d). Psychosocial burden is presented as mean of ratings on the 10-point Likert scales for psychosocial stress, psychiatric symptomatology, and quality of life. Ratings were performed retrospectively (before the pandemic: beginning of 2020; at the beginning of the pandemic: mid-March 2020), and for the current state (April/May 2020)

Course of psychosocial burden in patients with psychiatric disorders during different phases of the Covid-19 pandemic. a Course of the total sample (N = 210); differentiated by b gender (binary); c ICD-10 F-axes; d the ADNM-20 cut-off value indicating a high risk for adjustment disorder.* p < 0.05, ** p < 0.01, *** p < 0.001. Mean values with 95%-CIs (a, b, d) and Bonferroni corrected pairwise comparisons (a, b, d). Psychosocial burden is presented as mean of ratings on the 10-point Likert scales for psychosocial stress, psychiatric symptomatology, and quality of life. Ratings were performed retrospectively (before the pandemic: beginning of 2020; at the beginning of the pandemic: mid-March 2020), and for the current state (April/May 2020)

Gender differences

To analyze possible gender effects,2 an additional two-staged between-subjects factor (male vs. female) was added to the GLM (see Fig. 1b). In general, female patients showed significantly higher psychosocial burden scores (GLM: F(1, 180) = 5.67, p = 0.018, partial η2 = 0.03) with significant differences in pairwise comparisons for the phase at the beginning (M = 0.68, p < 0.05) and for the current state (M = 0.75, p = 0.024). However, the course of psychosocial burden followed the same pattern of increase and relief as described above (no significant interaction between scales and gender: GLM: F(2, 360) = 0.74, ns).

Differences between ICD-10 F-axes

Differences between the ICD-10 F-axes F2, F3, F4, F6, and F8 were analyzed by adding a five-staged between-subjects factor to the GLM.3 Significant differences between F-axes related to the general level of psychosocial burden (GLM: F(4, 191) = 5.64, p < 0.001, partial η2 = 0.11, see Fig. 1c). Patients with F3-axis and F4-axis diagnoses showed the highest levels of psychosocial burden, but significance was reached only for the comparison to patients with F2-axis diagnoses (p < 0.01). The course of psychosocial burden did not differ between the F-axes in terms of an interaction effect (GLM: F(8, 382) = 0.74, ns), and so, again, the course was found to be identical to that of the total sample.

Risk groups by ADNM-20

To identify specific risk groups exhibiting an unfavorable course of their mental health condition as the pandemic continues, we divided the sample into groups at high (n = 82) vs. low risk (n = 129) for adjustment disorder by the proposed cut-off of 47.5. In an additional GLM, we added a two-staged between-subjects factor, respectively, and traced the course of psychosocial burden. Gender (binary) was added as covariate, due to high correlation with ADNM-20 scores (r = 0.322, p < 0.01). Both ADNM-20 groups differed significantly in the experience of psychosocial burden (GLM: F(1, 177) = 22.49, p < 0.001, partial η2 = 0.11). Moreover, the analysis also revealed a significant interaction effect (GLM: F(2, 354) = 23.07, p < 0.001, partial η2 = 0.12, Fig. 1d): Whereas patients at low risk for adjustment disorder showed a slow decrease in psychosocial burden, patients at high risk for adjustment disorder experienced a continuous increase of psychosocial burden over the course of the pandemic.

Descriptive results and exploratory analyses of secondary outcomes

ADNM-20 sum score

For 211 of 213 patients complete data sets of the ADNM-20 were available (Msum score = 42.84, SD = 14.07). As shown in Table 2, higher sum scores correlated with female gender (r = 0.322, p < 0.01), i.e. women showed a significantly higher ADNM-20 sum score (M = 47.61, SD = 13.78) compared to men (M = 38.51, SD = 14.17; t(181) = 4.57, p < 0.001; see Fig. 2a). UNINANOVA was used to analyze differences between the ICD-10 F-axes (see Fig. 2b) and revealed significant variation between the axes F2, F3, F4, F6, and F8 (F(4, 192) = 2.66, p = 0.034)3. However, none of those significances survived Bonferroni correction (p ≥ 0.072).
Table 2

Descriptive data for sociodemographic variables and secondary endpoints

Variable1234567891011M (SD)/Freq. (%)
Sociodemographic variables
1. Age (in years)42.24 (16.93)
2. Gender (male:female; %)0.158*94:91 (44.1%, 42.7%)
3. Living space (in m2)0.0920.00492.00 (55.69)
4. Covid-19 risk group (yes:no; %)− 0.515**− 0.168*0.04173:140 (34.3%, 65.7%)
ADNM-20
5. ADNM-20 sum score− 0.0400.322**0.038− 0.04942.84 (14.07)
Most pronounced psychiatric symptoms
6. Vigilancea0.0140.218**0.048− 0.1180.459**5.25 (3.27)
7. Media usea− 0.147*0.067− 0.124− 0.0170.275**0.174*4.19 (3.58)
8. Observing disease symptoms of othersa− 0.1220.1280.0820.0890.431**0.425**0.274**3.68 (3.39)
9. Poor drivea− 0.0560.300**− 0.022− 0.0190.632**0.191**0.303**0.215**3.62 (3.11)
10. Self-observing of disease symptomsa− 0.0990.043− 0.0620.0610.459**0.429**0.229**0.608**0.314**3.53 (3.30)
Resilience
11. Positive changesb− 0.253**− 0.0500.1240.259**− 0.0770.0720.0360.110− 0.1020.0024.41 (3.59)
12. Opportunitiesb− 0.198**− 0.0790.0530.100− 0.1320.0330.0670.050− 0.1300.0210.532**3.14 (3.50)

Descriptive data presented as correlations, frequencies (Freq.), means (M), and standard deviations (SD). *p < 0.05. **p < 0.01. Captions: Gender (male = 1, female = 2); risk group for a severe course of Covid-19 (yes = 1, no = 2); ADNM-20 sum score (20 to 80 points)

amost pronounced psychiatric symptoms: items rated from 0 to 10

bresilience: items rated from 0 to 10. (N = 170; df = 168 to N = 213; df = 211)

Fig. 2

Pandemic-related symptom levels of adjustment disorder measured by the ADNM-20 in patients with psychiatric disorders. Differentiated by a gender (binary), N = 183; b by ICD-10 F-axes (F2 to F8), N = 197. *p < 0.05, **p < 0.01, ***p < 0.001. Mean values with 95%-CIs and Bonferroni corrected pairwise comparisons for the ADNM-20 sum score (range: 20 to 80 points)

Descriptive data for sociodemographic variables and secondary endpoints Descriptive data presented as correlations, frequencies (Freq.), means (M), and standard deviations (SD). *p < 0.05. **p < 0.01. Captions: Gender (male = 1, female = 2); risk group for a severe course of Covid-19 (yes = 1, no = 2); ADNM-20 sum score (20 to 80 points) amost pronounced psychiatric symptoms: items rated from 0 to 10 bresilience: items rated from 0 to 10. (N = 170; df = 168 to N = 213; df = 211) Pandemic-related symptom levels of adjustment disorder measured by the ADNM-20 in patients with psychiatric disorders. Differentiated by a gender (binary), N = 183; b by ICD-10 F-axes (F2 to F8), N = 197. *p < 0.05, **p < 0.01, ***p < 0.001. Mean values with 95%-CIs and Bonferroni corrected pairwise comparisons for the ADNM-20 sum score (range: 20 to 80 points)

General psychiatric symptoms and resilience

15 of 22 pre-defined psychiatric symptoms did not, or only increased slightly (M ≤ 3) during the pandemic (please see Supplementary Table S3 for an English translation of all items). The five psychiatric symptoms with the strongest increase were (1) increased vigilance (M = 5.25), (2) more media use (M = 4.19), (3) paying attention to symptoms of others (M = 3.68), (4) poor drive (M = 3.62), and (5) paying attention to symptoms of oneself (M = 3.53). Besides positive correlations between these items (r = 0.174 to 0.608, p < 0.05 to < 0.01), older age was negatively correlated with media use (r = -0.147, p < 0.05), and female gender correlated with increased vigilance (r = 0.218, p < 0.01) and poor drive (r = 0.300, p < 0.01). Finally, the ADNM-20 sum score correlated positively with the top five items for changed psychiatric symptoms (r = 0.275 to 0.632, all p < 0.01). Please see Table 2 for details. For both resilience items, responses scored M ≥ 3: (1) The perception that “for me, some things have changed in a positive way during the pandemic” and the perspective that “the pandemic also holds opportunities for me” were rated M = 4.41 and M = 3.14, respectively. Both items correlated positively with r = 0.532 (p < 0.01). Older age correlated negatively with both resilience items (r = -0.198 to -0.253, all p < 0.01). Not belonging to a Covid-19 risk group correlated positively with the perception of positive changes during the pandemic (r = 0.259, p < 0.01). Please see Table 2 for an overview.

Discussion

In this study, we showed that psychosocial burden in patients with pre-existing and current mental health disorders followed a distinct pattern of increase and relief in the early phase of the Covid-19 pandemic and during maximum social restrictions in Germany. Particularly, female gender and a stress response with severe symptoms of adjustment disorder were identified as factors predicting higher psychosocial burden and an unfavorable course of psychosocial burden over time. Most psychiatric symptoms remained unchanged during the pandemic, except for higher awareness/vigilance to symptoms, media use, and poor drive. From our data, we have first preliminary evidence that most patients also exhibited resilience as indicated by ratings on positive changes and opportunities during the pandemic.

Course of psychosocial burden

To our knowledge, this is the first study to report changes in psychosocial burden and psychiatric symptoms over time during the Covid-19 pandemic across a broad spectrum of psychiatric disorders. A recent longitudinal study presented a similar course with a reduction of stress-related symptoms within four weeks as the pandemic peaked, but focused on PTSD, anxiety, and depression in the general population [12]. Along the same line with an adaptation response to lockdown restrictions and shown by data from the general population, anxiety and/or depression levels declined during the first weeks of lockdown in UK [36, 37], even if initially increased in a very early phase of the pandemic [36]. Similar results from the Swiss Corona Stress Study also showed a decrease of anxiety levels (late April 2020 to May/June 2020) [38]. The COSMO study allows for comparisons with data from the German population before the outbreak of the pandemic. In contrast, this study found slightly increased psychological distress (anxiety and depression) but was confined to the first weeks of lockdown in Germany (late March to early April 2020, as published so far [7]). Another German study with population-based pre-pandemic reference data did not identify general differences in mental health conditions according to the WHO-5 well-being index and PHQ-D between 2018 and 2020 (late April to late May) [39]. Compared to these longitudinal data from the general population, patients with current psychiatric conditions in the present study showed higher baseline levels of symptoms before the pandemic but seemed to experience a stress response very similar to that of general population samples: The initial rise of psychosocial burden was followed by a decline, possibly reflecting adaption. In this matter, subsample analyses of a quota survey in UK isolated 27.2% of participants with self-reported, pre-existing psychiatric disorders showing initial higher levels of depression and anxiety, a lower well-being and a reduction of depressive symptoms from late March to early May 2020 [37]. However, longitudinal reference data from populations with current psychiatric disorders are hardly available so far. At first glance, a course of psychosocial burden indicative of a normal stress response and only an increase in a minority of psychiatric symptoms in this particularly vulnerable population seems encouraging. One reason might be that patients show an adaptive stress response and employ resilience strategies to protect their individual well-being. However, despite generally elevated ADNM-20 sum scores in this population, one must consider that Germany showed moderate SARS-CoV-2 incidence rates compared to other countries. Even in the early months of the rising pandemic, the German healthcare system withstood the pandemic challenge in spring 2020 without collapsing. Also, only moderate restrictions were enacted in Germany compared to many other countries. Additionally, one might speculate that some patients even took advantage from their pre-existing low levels of functioning. Social withdrawal and isolation together with reduced leisure activities are common features of many psychiatric disorders, and such patients may have already been used to social deprivation. Furthermore, avoidance behavior and home confinement were legitimated by governmental regulations and may have contributed to the observed reduction in psychosocial burden. Treatment continuation, as realized via service hotlines, emergency contacts and early implementation of telepsychiatric services, might have also contributed to the rather small, partial and temporary impact on the psychosocial burden of the psychiatric population studied here.

Risk groups

The identification of risk groups for clinical worsening is essential for timely and specific intervention. In these terms and with these first data, the Goe-BSI provides a reliable and valid measure (please see Supplementary Information S1) sensitive for change and particularly suitable for detection of risk groups for an unfavorable outcome. Being female has previously been identified as a risk factor for higher levels of anxiety, depression, and stress [7, 14, 23, 36–38]. Furthermore, our finding of a higher psychosocial burden in female patients was paralleled by elevated sum scores of the ADNM-20. Irrespective of gender, the ADNM-20 provided good discriminant validity and allowed to detect patients at risk for unfavorable trajectories of psychosocial burden. Importantly, 39% of the present patient sample were indicative of adjustment disorder compared to 44% of first-onset adjustment disorder in Covid-19 patients in China [40] and 16% in Iran [31]. As published so far, only two studies included assessments for adjustment disorder [14], while most projects focused on depression, anxiety, stress, and PTSD symptoms. Such, 8% of healthy medical staff members in Switzerland showed adjustment disorder according to the ADNM-20 [41]. Using the International Adjustment Disorder Questionnaire (IADQ), Rossi et al. found an increase in adjustment disorder symptoms in the general population during the first weeks of lockdown in Italy [14]. They also reported an association of quarantine and other recent Covid-19-related stressful life events with depression, anxiety, insomnia, stress, PTSD, and adjustment disorder symptoms. The lack of such relations in our sample might be due to lower rates of Covid-19 infections (n = 1) and the small proportion of patients with Covid-19-related stressors (e.g., quarantine, contact to infected individuals).

Strengths and limitations

Data presented refers to outpatients only. Inpatients might have reacted with a milder stress response to pandemic-related changes as a result of different environmental conditions—specifically, hospitalization may have served as a protective factor. However, to keep the sample as homogenous as possible, this project focusses on outpatients who experienced environmental conditions more similar to those of the general population than an inpatient sample. Besides that, participants of this study continuously received treatment even though under different conditions (e.g. telemedicine). Trajectories of patients (1) without access to mental health services or (2) those who discontinued treatment might have resulted in a different and more pronounced stress response. Both aspects—hospitalization and absence of mental health care—may convey a potential inclusion bias. Some ICD-10 diagnoses were underrepresented in this convenience sample, e.g. F0, F1, and F5. The low number of patients with organic mental disorders may be explained by the inability to give informed consent which is common in patients with dementia and related disorders. F5-diagnoses were most likely underrepresented because in Germany they are primarily treated by specialists for psychosomatic medicine rather than by psychiatrists. On the other hand, patients with gender identity disorders (F64.*) and adult Asperger’s syndrome (F84.5) were likely overrepresented in our sample, which results from the availability of specialized outpatient services in our department. Regarding substance use disorders (F1) a higher amount of relapses [27], and for psychotic disorders (F2) an increase of symptoms can be expected [42]. In this study, analyses have been performed in clusters of main/primary diagnosis. Hence, future analyses of types and amount of comorbid/secondary diagnoses may provide more exhaustive results. Still, our data showed that similar and robust patterns can be derived across genders and major ICD-10 F-axes. Diagnostic accuracy is a major strength of our approach. Diagnoses do not rely on self-report like in many online surveys [23, 37], but were made by the patients’ treating clinicians. Furthermore, applying the Goe-BSI as telephone interview enabled us to obtain a nearly complete data set. In addition, with an approach combining current and retrospective data, we could create pseudo-trajectories of psychosocial burden during the pandemic. Certainly, retrospective estimation has to be interpreted cautiously and may be susceptible for confounding.

Conclusion

Future prospective studies need to address whether a—presumably temporary—relief of psychosocial burden can be preserved or will finally revert to worsening of pre-existing mental health conditions as the pandemic continues. Detrimental long-term effects on mental health issues in patients with psychiatric disorders and the general population have to be expected considering long incubation times before relevant deterioration or newly developed mental health disorders can be observed. This scenario holds considerable challenges for the healthcare system and calls for sensitive tools to detect risk groups. Although a similar evolution pattern of psychosocial burden during an early phase of the pandemic was found across all F-axes in this study, patients with different psychiatric disorders would still require specialized treatment. Complementary, telemedicine already holds digital opportunities for patients with a particular risk, to prevent such worsening and might enable timely, intensified, and specific treatment as well as treatment continuity. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 24 kb) Supplementary file2 (DOCX 16 kb) Supplementary file3 (DOCX 18 kb)
  41 in total

1.  Mental Health Response to the COVID-19 Outbreak in China.

Authors:  Junying Zhou; Liu Liu; Pei Xue; Xiaorong Yang; Xiangdong Tang
Journal:  Am J Psychiatry       Date:  2020-05-07       Impact factor: 18.112

2.  Development and validation of a self-report for the assessment of adjustment disorders.

Authors:  Franziska Einsle; Volker Köllner; Stephanie Dannemann; Andreas Maercker
Journal:  Psychol Health Med       Date:  2010-10       Impact factor: 2.423

3.  COVID-19 Pandemic and Lockdown Measures Impact on Mental Health Among the General Population in Italy.

Authors:  Rodolfo Rossi; Valentina Socci; Dalila Talevi; Sonia Mensi; Cinzia Niolu; Francesca Pacitti; Antinisca Di Marco; Alessandro Rossi; Alberto Siracusano; Giorgio Di Lorenzo
Journal:  Front Psychiatry       Date:  2020-08-07       Impact factor: 4.157

4.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.

Authors:  Aravinthan Varatharaj; Naomi Thomas; Mark A Ellul; Nicholas W S Davies; Thomas A Pollak; Elizabeth L Tenorio; Mustafa Sultan; Ava Easton; Gerome Breen; Michael Zandi; Jonathan P Coles; Hadi Manji; Rustam Al-Shahi Salman; David K Menon; Timothy R Nicholson; Laura A Benjamin; Alan Carson; Craig Smith; Martin R Turner; Tom Solomon; Rachel Kneen; Sarah L Pett; Ian Galea; Rhys H Thomas; Benedict D Michael
Journal:  Lancet Psychiatry       Date:  2020-06-25       Impact factor: 27.083

5.  COVID-19 and implications for eating disorders.

Authors:  Fernando Fernández-Aranda; Miquel Casas; Laurence Claes; Danielle Clark Bryan; Angela Favaro; Roser Granero; Carlota Gudiol; Susana Jiménez-Murcia; Andreas Karwautz; Daniel Le Grange; Jose M Menchón; Kate Tchanturia; Janet Treasure
Journal:  Eur Eat Disord Rev       Date:  2020-05

6.  Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study.

Authors:  Daisy Fancourt; Andrew Steptoe; Feifei Bu
Journal:  Lancet Psychiatry       Date:  2020-12-09       Impact factor: 27.083

7.  Mental health in the COVID-19 pandemic.

Authors:  W Cullen; G Gulati; B D Kelly
Journal:  QJM       Date:  2020-05-01

8.  Online mental health services in China during the COVID-19 outbreak.

Authors:  Shuai Liu; Lulu Yang; Chenxi Zhang; Yu-Tao Xiang; Zhongchun Liu; Shaohua Hu; Bin Zhang
Journal:  Lancet Psychiatry       Date:  2020-02-19       Impact factor: 27.083

9.  A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations.

Authors:  Jianyin Qiu; Bin Shen; Min Zhao; Zhen Wang; Bin Xie; Yifeng Xu
Journal:  Gen Psychiatr       Date:  2020-03-06

10.  Psychological Effects of the COVID-19 Imposed Lockdown on Adults with Attention Deficit/Hyperactivity Disorder: Cross-Sectional Survey Study.

Authors:  Marios Adamou; Tim Fullen; Karl Abbott; Claire Smith; Nazmeen Galab; Isobel Mackintosh; Deborah Lowe
Journal:  JMIR Form Res       Date:  2020-12-15
View more
  10 in total

1.  [Psychiatric Rehabilitation in Austria - A Comparison of Symptoms at Admission Before and During COVID-19 Pandemic, as well as Rehabilitation Success].

Authors:  Birgit Senft; Michaela Krenn; Doris Petz; Sigurd Hochfellner
Journal:  Rehabilitation (Stuttg)       Date:  2022-01-11       Impact factor: 1.072

2.  Perceived empowerment and the impact of negative effects of the COVID-19 pandemic on the quality of life of persons with severe mental illness.

Authors:  Annabel Sandra Mueller-Stierlin; Friedrich Meixner; Jutta Lehle; Anne Kohlmann; Mara Schumacher; Stefanie Woehler; Anke Haensel; Sabrina Reuter; Katrin Herder; Nicole Bias; Thomas Becker; Reinhold Kilian
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

3.  Impact of the COVID-19 pandemic on depression, anxiety, loneliness, and satisfaction in the German general population: a longitudinal analysis.

Authors:  Nora Hettich; Theresa M Entringer; Hannes Kroeger; Peter Schmidt; Ana N Tibubos; Elmar Braehler; Manfred E Beutel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-06-09       Impact factor: 4.519

4.  Changes and Challenges in Inpatient Mental Health Care During the First Two High Incidence Phases of the COVID-19 Pandemic in Germany - Results From the COVID Ψ Psychiatry Survey.

Authors:  Hauke Felix Wiegand; Anna-Lena Bröcker; Mandy Fehr; Niklas Lohmann; Birgit Maicher; Nikolaus Röthke; Mike Rueb; Paula Wessels; Moritz de Greck; Andrea Pfennig; Stefan Unterecker; Oliver Tüscher; Henrik Walter; Peter Falkai; Klaus Lieb; Lars Peer Hölzel; Kristina Adorjan
Journal:  Front Psychiatry       Date:  2022-04-27       Impact factor: 5.435

5.  Emotion-related impulsivity predicts increased anxiety and depression during the COVID-19 pandemic.

Authors:  Sheri L Johnson; Patricia A Porter; Kiana Modavi; Amelia S Dev; Jennifer G Pearlstein; Kiara R Timpano
Journal:  J Affect Disord       Date:  2022-01-11       Impact factor: 4.839

6.  Developing a Brief Tele-Psychotherapy Model for COVID-19 Patients and Their Family Members.

Authors:  Bruno Biagianti; Silvana Zito; Chiara Fornoni; Valeria Ginex; Marcella Bellani; Cinzia Bressi; Paolo Brambilla
Journal:  Front Psychol       Date:  2021-12-02

Review 7.  The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.

Authors:  Nastaran Sabetkish; Alireza Rahmani
Journal:  Health Sci Rep       Date:  2021-10-01

Review 8.  Stress, PTSD, and COVID-19: the Utility of Disaster Mental Health Interventions During the COVID-19 Pandemic.

Authors:  Patricia Watson
Journal:  Curr Treat Options Psychiatry       Date:  2022-02-21

9.  Changes in Prevalence and Severity of Domestic Violence During the COVID-19 Pandemic: A Systematic Review.

Authors:  Freya Thiel; Verena C S Büechl; Franciska Rehberg; Amera Mojahed; Judith K Daniels; Julia Schellong; Susan Garthus-Niegel
Journal:  Front Psychiatry       Date:  2022-04-13       Impact factor: 5.435

10.  The relationship between health worry, work distress, and affective symptoms during the COVID-19 pandemic: The mediating role of hopelessness and helplessness.

Authors:  Hannah C Broos; Maria M Llabre; Patrice G Saab; Rafael O Leite; Jamie H Port; Kiara R Timpano
Journal:  Br J Clin Psychol       Date:  2022-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.